Search research articles
Contact Us
Filters
Showing results (161-170 of 418) with videos related to
Page
of 42
Sort By:
The Oncologist
|
May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Ryan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib
Melissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
April A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Kensuke Tateishi, A John Iafrate, Quan Ho, et al.
Plos One
|
March 26, 2013
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling
Brijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, et al.
Cancer Chemotherapy and Pharmacology
|
April 14, 2010
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M Traynor, Maureen Hewitt, Glenn Liu, et al.
Cancer
|
June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
Daniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Victoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cancer Research
|
January 11, 2007
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells
Keiran S M Smalley, Rooha Contractor, Nikolas K Haass, et al.
Page
of 42
Search research articles
Search
Showing results (161-170 of 418) with videos related to
Sort By:
Page
of 42
The Oncologist
|
May 20, 2015
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Ryan J Sullivan, Nageatte Ibrahim, Donald P Lawrence, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2014
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib
Melissa A Wilson, Fengmin Zhao, Richard Letrero, et al.
Investigational New Drugs
|
May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 13, 2016
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB
April A N Rose, Matthew G Annis, Dennie T Frederick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Kensuke Tateishi, A John Iafrate, Quan Ho, et al.
Plos One
|
March 26, 2013
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling
Brijal M Desai, Jessie Villanueva, Thierry-Thien K Nguyen, et al.
Cancer Chemotherapy and Pharmacology
|
April 14, 2010
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors
Anne M Traynor, Maureen Hewitt, Glenn Liu, et al.
Cancer
|
June 8, 2012
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy
Daniel C Cho, Thomas E Hutson, Wolfram Samlowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2019
Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Victoria E Wang, Jenny Y Xue, Dennie T Frederick, et al.
Cancer Research
|
January 11, 2007
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells
Keiran S M Smalley, Rooha Contractor, Nikolas K Haass, et al.
Page
of 42